Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ZARS Pharma Inc.
• Treatments: Lidocaine; Tetracaine

Criteria

Inclusion Criteria:

• be at least 18 years of age

• have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 myofascial trigger points

• have trigger points confined to the upper back, shoulder, and neck

Exclusion Criteria:

• have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit

• have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit

• have used any injected pain medication with 28 days preceding the Screening/Baseline Visit

• are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)

Other protocol-defined inclusion/exclusion criteria may apply.